We just can't afford it, another CR would be a drop in the ocean for what developing a drug would cost for example a phase III trial would include a few hundred patients at least and we aren't even up to that phase yet.
Our ADAPT products have already been developed and we can sell them right away. Where pumping extra money into something that might be a success years down the track is just a gamble.
Plus we could still hold some equity share and we won't have to worry where the funding will come from.
AHZ Price at posting:
26.0¢ Sentiment: Buy Disclosure: Held
(20min delay)